Nuvation Bio Inc.

Corporate Updates In June 2025, the Company received $200 million as part of non-dilutive financing agreements with Sagard Healthcare Partners, including $150 million in royalty interest financing and $50 million under a term loan following U.

SEC original ↗Nuvation Bio Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

The Company has access to an additional $50 million under the term loan at its option until June 30, 2026.

SEC original ↗Nuvation Bio Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted, convertible debt, revenue recognition, interest expense and depreciation expense.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

Marketable Securities Debt securities have been classified as available-for-sale which may be sold before maturity or are not classified as held to maturity or trading.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

Marketable debt securities classified as available-for-sale are carried at fair value with unrealized gains or losses reported in 6 other comprehensive income (loss).

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

Realized gains and losses on both debt and equity securities are included in other (expense) income, net.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients lives.

SEC original ↗Nuvation Bio Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

and subsidiaries ( Nuvation Bio ), a Delaware corporation, is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients lives.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Company s operations are focused on oncology development activities.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

The CODM utilizes the Company s strategic product development roadmaps and financial models as a key input to resource allocation.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

(NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.

SEC original ↗Nuvation Bio Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients lives.

SEC original ↗Nuvation Bio Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on August 7, 2025 under the heading Risk Factors, and other documents that Nuvation Bio has filed or will file with the SEC.

SEC original ↗Nuvation Bio Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

These statements speak only as of the date of this report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026

New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

SEC original ↗Nuvation Bio Inc. — 10-Q Quarterly report10-QAug 6, 2026